---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-23-000069"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T12:56:53.518479+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra Q3 revenues down 0.7%, GAAP EPS $0.24; adjusts FY23 guidance lower

## Summary
- Q3 revenue $382.4M, reported -0.7% YoY; organic ex-Boston +7.1%.
- GAAP EPS $0.24 vs $0.60; adjusted EPS $0.76 vs $0.86.
- Codman Specialty Surgical +7.4% organic; Tissue Technologies -15.1% organic due to Boston recall returns.
- FY23 revenue guidance cut to $1.541-1.547B; adjusted EPS $3.10-3.14.
- Boston facility restart on track for Q4'23; commercial distribution expected mid-to-late Q2'24.

## SEC filing metadata
- accession: 0000917520-23-000069
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752023000069/0000917520-23-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752023000069/iart-20231025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-23-000069
- JSON: https://secwatch.observer/filing/0000917520-23-000069.json
- Plain text: https://secwatch.observer/filing/0000917520-23-000069.txt

## Key facts
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported third quarter ending September 30, 2023 results: revenue $382.4 million, net income $19.5 million, EPS $0.24 per diluted share.
  - Period: third quarter ending September 30, 2023
  - Revenue: $382.4 million
  - Net income: $19.5 million
  - EPS: $0.24 per diluted share
  - Result: reported results
  source text: global medical technology company, today reported financial results for the third quarter ending September 30, 2023. Third Quarter 2023 Highlights • Third quarter revenues of $382.4 million declined 0.7% on a reported basis and declined 0.4% on an organic basis compared to the prior year and increased 7.1% on an organic basis excluding Boston • Third quarter GAAP
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000069/0000917520-23-000069-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.